---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-059900"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2025-06-16T23:59:59+00:00"
generated_at: "2026-05-19T06:05:39.204100+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BrainStorm reports 90% of ALS patients in NurOwn EAP survived over 5 years

## Summary
- 9 of 10 NurOwn EAP participants survived >5 years from symptom onset vs. ~10% typical survival in ALS.
- Median survival in small cohort was 6.8 years; only death was elective euthanasia.
- Company says data strengthens rationale for Phase 3b trial of NurOwn in ALS under FDA SPA.
- CEO and CMO highlighted clinically meaningful observation in press release.

## SEC filing metadata
- accession: 0001104659-25-059900
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2025-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465925059900/0001104659-25-059900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465925059900/tm2518123d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-059900
- JSON: https://secwatch.observer/filing/0001104659-25-059900.json
- Plain text: https://secwatch.observer/filing/0001104659-25-059900.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.